Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Ihle, NT and Lemos, R and Schwartz, D and Oh, J and Halter, RJ and Wipf, P and Kirkpatrick, L and Powis, G (2009) Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Molecular Cancer Therapeutics, 8 (1). 94 - 100. ISSN 1535-7163

[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade is an important component of the insulin signaling in normal tissues leading to glucose uptake and homeostasis and for cell survival signaling in cancer cells. Hyperglycemia is an on-target side effect of many inhibitors of PI3K/Akt signaling including the specific PI3K inhibitor PX-866. The peroxisome proliferator-activated receptor γ agonist pioglitazone, used to treat type 2 diabetes, prevents a decrease in glucose tolerance caused by acute administration of PX-866. Our studies have shown that pioglitazone does not inhibit the antitumor activity of PX-866 in A-549 non-small cell lung cancer and HT-29 colon cancer xenografts. In vitro studies also showed that pioglitazone increases 2-[1- 14 C]deoxy-D-glucose uptake in L-6 muscle cells and prevents inhibition of 2-deoxyglucose uptake by PX-866. Neither pioglitazone nor PX-866 had an effect on 2-deoxyglucose uptake in A-549 lung cancer cells. In vivo imaging studies using [ 18 F]2-deoxyglucose (FDG) positron emission tomography showed that pioglitazone increases FDG accumulation by normal tissue but does not significantly alter FDG uptake by A-549 xenografts. Thus, peroxisome proliferator-activated receptor γ agonists may be useful in overcoming the increase in blood glucose caused by inhibitors of PI3K signaling by preventing the inhibition of normal tissue insulin-mediated glucose uptake without affecting antitumor activity. Copyright © 2009 American Association for Cancer Research.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Ihle, NT
Lemos, R
Schwartz, D
Oh, J
Halter, RJ
Wipf, Ppwipf@pitt.eduPWIPF
Kirkpatrick, L
Powis, G
Date: 1 January 2009
Date Type: Publication
Journal or Publication Title: Molecular Cancer Therapeutics
Volume: 8
Number: 1
Page Range: 94 - 100
DOI or Unique Handle: 10.1158/1535-7163.mct-08-0714
Schools and Programs: Dietrich School of Arts and Sciences > Chemistry
Refereed: Yes
ISSN: 1535-7163
MeSH Headings: Animals; Antineoplastic Agents--pharmacology; Cell Line, Tumor; Disease Progression; Glucose--metabolism; Glucose Transport Proteins, Facilitative--metabolism; Glucose-6-Phosphate--analogs & derivatives; Glucose-6-Phosphate--metabolism; Gonanes--pharmacology; Humans; Hyperglycemia--enzymology; Hyperglycemia--prevention & control; Mice; Neoplasms--drug therapy; Neoplasms--pathology; PPAR gamma--agonists; PPAR gamma--metabolism; Phosphatidylinositol 3-Kinases--metabolism; Signal Transduction--drug effects; Thiazolidinediones--pharmacology; Thiazolidinediones--therapeutic use; Xenograft Model Antitumor Assays
Other ID: NLM NIHMS87811, NLM PMC2633941
PubMed Central ID: PMC2633941
PubMed ID: 19139117
Date Deposited: 03 Jul 2013 14:49
Last Modified: 13 Oct 2017 21:56
URI: http://d-scholarship.pitt.edu/id/eprint/19216

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item